In 2020, right before the COVID pandemic really got going, @CarlJune and I debated #Cell #immunothewrapy vs #bispecific #TcellEngagers. I think many of the points we discussed and debated will play out over the next few years. Powerful technologies that are already helping cancer patients, but also will benefit from a great deal of additional development.

Here is an excellent summary of what is known about #bispecific #antibodies in #cancer #immunotherapy.

#OpenAccess article in Frontiers in #Immunology: https://www.frontiersin.org/articles/10.3389/fimmu.2022.1035276/full